Lineage Cell Therapeutics Highlights R&D Momentum Amid Losses

Lineage Cell Therapeutics, Inc. ((LCTX)) has held its Q1 earnings call. Read on for the main highlights of the call.

Lineage Cell Therapeutics struck an upbeat tone on its latest earnings call, emphasizing scientific and operational momentum across its cell therapy pipeline despite widening losses and modest revenue. Management highlighted a strong balance sheet and multiple potential funding sources, arguing that progress in manufacturing scale, partnerships, and clinical data outweighs current financial and program risks.

AlloSCOPE Manufacturing Platform Expansion

Lineage reported successful expansion of its AlloSCOPE manufacturing platform, adding a two-tiered banking system that moves cells from master to working to clinical banks. Management said the approach has already yielded an FDA-cleared final product, with illustrative math suggesting capacity for up to a million vials and potential cost-per-dose in the low hundreds of dollars.

Launch of COR1 Corneal Endothelial Cell Program

The company introduced COR1 as a wholly owned program targeting corneal endothelial disease, including Fuchs dystrophy and other corneal conditions. Early preclinical work has produced cryopreservable, off-the-shelf corneal endothelial cells that meet Lineage’s initial identity, morphology, and functional benchmarks, with translational studies next on the path toward possible IND-enabling work.

OpRegen Partner Momentum and Long-Term Data

For OpRegen, Lineage’s partner Roche/Genentech reported that vision gains in some patients have persisted for at least three years following a single administration. The partners also expanded the GAlette study to 17 sites, with 11 new locations recently opened, signaling increased investment and operational scale in this late-stage ophthalmology collaboration.

ILT1 Manufacturing Milestone for Islet Program

Lineage achieved its first internal milestone for the ILT1 program by demonstrating a highly homogenized, scalable, fully suspension-based process for undifferentiated pluripotent cells at 0.5-liter scale. The team has now progressed into multi-liter formats to build feedstock that can ultimately support the massive islet dose requirements anticipated in type 1 diabetes.

OPC1 Device Safety and Clinical Progress

In spinal cord injury, the DOSED trial evaluating the OPC1 delivery device is proceeding without unexpected safety issues or meaningful design changes. The study has expanded to a second site at Rancho Research Institute, and the first chronic spinal cord injury participant treated under the trial is nearing a key one-year follow-up milestone.

ReSonance Partnership and Manufacturing Runs

Lineage reported steady progress in its ReSonance auditory neuronal cell program, partnered with William Demant. The company has completed three engineering manufacturing runs and is preparing for GMP production, while Demant has committed up to $12 million to preclinical activities, with about two-thirds of that expected as reimbursement to Lineage.

Strengthened Scientific and Clinical Leadership Bench

Management underscored governance upgrades with the formation of a Scientific Advisory Board and the appointment of Dr. Joachim Froebus as a founding member. In parallel, the company hired Dr. Priyantha Harath as Senior Vice President and Head of Clinical, bolstering Lineage’s capabilities in late-stage development, regulatory strategy, and clinical execution.

Cash Position and Potential Near-Term Funding

Lineage ended the quarter with $53.4 million in cash, which management believes can fund operations into 2028 under a roughly $30 million per year spend. Additional liquidity could come from approximately $32 million of warrants, which may be exercised if OpRegen advances to a multicenter trial, and from up to $615 million of potential milestones under the Roche/Genentech collaboration.

Modest but Growing Collaboration Revenue

Revenue remains small but is trending upward, with about $1.7 million booked in the quarter compared with $1.5 million a year earlier. The 13.3% growth is mainly driven by collaboration income, reinforcing that Lineage is still in a pre-commercial stage where its value hinges more on clinical and partnership progress than on product sales.

Rising Operating Expenses and Losses

Operating expenses climbed to $9.3 million from $8.0 million, reflecting stepped-up investment in R&D and modestly higher G&A. Research and development costs rose to $4.2 million, driven by incremental spending on OPC1, ReSonance, and other preclinical programs, while general and administrative expenses ticked up to $5.1 million as the company supports a broader pipeline.

Net Loss and Per-Share Impact

Net loss attributable to Lineage widened to $4.8 million versus $4.1 million in the prior-year period, aligning with the scale-up in operating activity. Loss per share came in at $0.02 basic and $0.03 diluted, compared with $0.02 on both bases a year ago, levels that investors will weigh against the company’s extended cash runway and pipeline advancement.

Dependence on Partner Decisions for OpRegen

Despite strong OpRegen data and site expansion, Lineage acknowledged that further development steps are largely in the hands of Roche/Genentech. The timing and structure of any multicenter controlled trial, as well as public disclosures on GAlette results, depend on partner decisions, creating uncertainty around the pace of value realization in this key program.

Islet Program Scale-Up and Technical Risk

Management highlighted considerable technical risk in scaling its islet cell therapy, noting that each patient may require close to a billion cells. Making the program commercially viable could demand bioreactor volumes near 80 liters, pushing the limits of the AlloSCOPE 5D platform and raising open questions about differentiation efficiency and product homogeneity at extreme scale.

Photoreceptor Program Reset

The company’s photoreceptor initiative suffered a timing setback after Lineage terminated a third-party intellectual property agreement to improve program economics. While this move may benefit long-term margins, it effectively pushes the program back to an earlier stage and requires the team to re-advance the asset without relying on the former partner’s IP.

CIRM Grant Outcome and OPC1 Funding Mix

Lineage did not secure a CIRM grant for OPC1 in the first application cycle and has since reapplied, but management stressed that the program can proceed without that funding. Still, the absence of a non-dilutive grant in the near term increases reliance on internal cash and other potential funding to sustain the spinal cord injury agenda.

Enrollment Challenges in Subacute OPC1 Cohort

The company flagged recruitment hurdles in the subacute OPC1 spinal cord injury cohort, where eligible patients must fall within a 21 to 42-day post-injury window and live near participating centers. Lineage believes chronic patient enrollment will be easier, but subacute recruitment constraints could slow overall trial timelines and data readouts.

Forward-Looking Outlook and Capital Discipline

Management reiterated that its $53.4 million cash balance, expected to last into 2028, provides a solid foundation to pursue multiple clinical and manufacturing milestones. They emphasized disciplined annual spending around $30 million, while highlighting upside optionality from potential warrant exercises, large pharma milestones, and further validation of the AlloSCOPE platform and partnered programs.

Lineage’s latest call portrayed a company leaning into its manufacturing edge and partnerships to build long-term value, even as losses expand and key programs face technical and timing risks. For investors, the story hinges on whether durable clinical data, scaling breakthroughs, and big pharma collaborations can translate into future commercial opportunities before the cash runway runs out.